TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04638855

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medicurtain®
Description: Anti-adhesion barrier (Medicurtain® 5ml prefilled syringe after hysteroscopy surgery)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: No device after hysteroscopy surgery
Study: NCT03799978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468
Description: ACT-541468 50 mg film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468
Description: ACT-541468 50 mg film-coated tablets
Study: NCT03320343

Intervention type: OTHER
Intervention: MRI
Description: 3D morphological MRI and diffusion tensor imaging
Study: NCT02580578

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention is administered in this study.
Study: NCT01306461

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol and Tafluprost
Description: Preservative-free Timolol eye drops administered twice daily concomitantly with preservative-free Tafluprost eye drops administered once daily~Treatment period 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed Dose Combination of tafluprost and timolol
Description: Preservative-free Fixed Dose Combination of tafluprost and timolol eye drops administered once daily.~For masking purposes also: vehicle for timolol administered twice daily~Treatment period 6 months
Study: NCT01620489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 1.8 mg administered once daily subcutaneously (s.c., under the skin) as add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered once daily subcutaneously (s.c., under the skin) as add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen.
Study: NCT02314520

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: peripherally inserted central catheter
Description: Any complication associated with central access

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: centrally inserted central catheter
Description: Central access not associated with any complication
Study: NCT00647166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroid and azathioprine
Description: * Corticosteroid 1 mg/kg/day with a conventional decrease dose~* Azathioprine : 2 mg/kg/day during one year in 2 to 3 times a day by oral route
Study: NCT01690871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235
Description: Patients will be provided with an adequate supply of study treatment for self-administration at home. Unless otherwise warranted, new study drug packages will be provided to the patient at Cycle 1 Day 1 (start of treatment) and at Day 1 of each following treatment cycle. The first dose of BEZ235 (Cycle1 Day1) must be taken at the hospital.
Study: NCT00930644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teduglutide
Description: 0.05 mg/kg/day subcutaneously taken once per day for 24 months
Study: NCT04096261

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test
Description: Diagnostic Test: Contrast agentenhanced MRI using Gadovist by using the contrast agent Gadovist we aim to visualize the blood-brain barrier. Furthermore, we aim to measure a newly developed biomarker of the blood-brain barrier in the cerebro-spinal fluid. And sleep quality measurement with a polysomnography.
Study: NCT00647166

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: corticosteroid and placebo
Description: * Corticosteroid 1 mg/kg/day with a conventional decrease dose~* Placebo : 2 mg/kg/day during one year in 2 to 3 times a day by oral route
Study: NCT04096261

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test
Description: Diagnostic Test: Contrast agentenhanced MRI using Gadovist by using the contrast agent Gadovist we aim to visualize the blood-brain barrier. Furthermore, we aim to measure a newly developed biomarker of the blood-brain barrier in the cerebro-spinal fluid. And sleep quality measurement with a polysomnography.

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test
Description: Diagnostic Test: Contrast agentenhanced MRI using Gadovist by using the contrast agent Gadovist we aim to visualize the blood-brain barrier. Furthermore, we aim to measure a newly developed biomarker of the blood-brain barrier in the cerebro-spinal fluid. And sleep quality measurement with a polysomnography.

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test
Description: Diagnostic Test: Contrast agentenhanced MRI using Gadovist by using the contrast agent Gadovist we aim to visualize the blood-brain barrier. Furthermore, we aim to measure a newly developed biomarker of the blood-brain barrier in the cerebro-spinal fluid. And sleep quality measurement with a polysomnography.
Study: NCT02257632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Description: Administered as an intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Description: Administered as an intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept 2 mg
Description: Administered as an intravitreal injection
Study: NCT01325519

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video decision aid
Description: video
Study: NCT02650388

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive fuction, quality of life
Description: To test the above score in patients undergoing TAVI
Study: NCT04494503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-2575
Description: APG-2575 orally once daily, every 28 days as a cycle.
Study: NCT04194905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 0.1 mg and Ethinyl estradiol 0.02 mg Test Product
Description: Coated Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel 0.1 mg and Ethinyl estradiol 0.02 mg Reference Product
Description: Coated Tablets
Study: NCT03810833

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brilliance device sensor
Description: Two separate sensors will be attached via standard, single-use adhesive pads to the left and right pectoralis major on each participant.
Study: NCT04378010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-305 1.5 mg
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-305 2 mg
Description: Tablet
Study: NCT04494503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-2575
Description: APG-2575 orally once daily, every 28 days as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-2575
Description: APG-2575 orally once daily, every 28 days as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375mg/m2 ivgtt on C1D8 and 500mg/m2 ivgtt on C2-6D1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib 420mg orally once daily during C1D8-28 and following cycles.
Study: NCT02857816

Intervention type: DEVICE
Group type: OTHER
Intervention: NURO System PTNM Therapy
Study: NCT04378010

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet
Study: NCT01873846

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silicone Hydrogel Contact Lens
Study: NCT01889329

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RUTF-1
Description: Made from local food ingredients

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RUTF-2
Description: Made from local food ingredients

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plumpynut
Description: Commercially made from peanut paste
Study: NCT03563599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telacebec (Q203)
Description: High, Mid, Low dose of telacebec

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifafour e-275
Description: RHZE (R=rifampicin: H=isoniazid: Z=pyrazinamide: E=ethambutol)
Study: NCT04227431

Intervention type: OTHER
Intervention: Insulin degludec
Description: Participants have been treated with Tresiba® (insulin degludec) for at least 20 weeks before entering the study. The study will be based on data already recorded in participants' medical records for approximately the last year and no new tests or procedures are required as part of the study.
Study: NCT01070368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Commercial extract and in-house wheat extract
Description: Patients with a history of wheat allergy underwent two skin test extracts, and open challenge with wheat. A blood test for specific IgE was performed in the same time.
Study: NCT02682303

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elastic Bandage (Idealplast C®)
Description: Elastic bandage~One anchor strip is applied around the ankle with no tension applied to the tape to avoid restricting blood flow. A supporting stirrup strap is applied from the inside of the ankle, under the heel with no tension up to this point. As the tape is passed up the outside of the ankle tension is applied to the tape with the foot in slight dorsiflexion and secured to the anchor strap (black arrow).~For heel lock, a second strip is applied on the outside of the ankle, taken across the front of the ankle and just above the bony part on the inside of the ankle and back towards the heel (red arrow). Then taken around and under the heel back the way you have just come and around the front of the ankle (orange arrow). The tape then passes above the bony part of the ankle on the outside and diagonally towards the heel, across to the inside of the ankle then around the top to finish

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pretape cramer® (non standarized tape)
Description: Pretape cramer® was used.~The individual is in supine position keeping the foot and ankle in a neutral position.~The strip (I) is applied with not stretch in the outside of the leg just above the ankle, and then the rest of the strip is applied on the outside of the ankle and under the heel.~This is the only intervention carried out in this group.
Study: NCT00937001

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy/Ultrasound
Description: obtain muscle biopsies at approximately 14 days of ICU, muscle ultrasound at 3-4 timepoints
Study: NCT02356965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Single dose of sublingual investigational medication administered when subjects develop moderate to severe pain after third molar extraction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Single dose of sublingual investigational medication administered when subjects develop moderate to severe pain after third molar extraction.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Ketamine)
Description: Sublingual sugar pill developed to mimic ketamine sublingual dose.
Study: NCT00253097

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Intervention
Description: Patients allocated to the intervention group have 4 visits by a study nurse. She will measure patient's blood pressure (BP) by standardized meathods, inform the patient about the target BP, stress the importance of lowering the BP and in case of elevated BP she advices the patient to go the the GP for further control. She advises about smoking cessation, reduction of alcohol consumption, loss of excess body weigt and stresses the importance of physical activity as appropriate

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Patients allocated to the intervention group have 4 visits by a study nurse. She will measure patient's blood pressure (BP) by standardized meathods, inform the patient about the target BP, stress the importance of lowering the BP and in case of elevated BP she advices the patient to go the the GP for further control. She advises about smoking cessation, reduction of alcohol consumption, loss of excess body weigt and stresses the importance of physical activity as appropriate
Study: NCT00623025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creon 25000
Description: 6 to 9 capsules Creon 25000 per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 to 9 capsules placebo per day
Study: NCT04505514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Isomaltoside 1000
Description: single dose of 1000 mg iron isomaltoside diluted in 100 ml of 0.9% sodium chloride, infused intravenously over ≥ 20 minutes.~- infusion set will be covered for blinding

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 100 ml of 0.9% sodium chloride, infused intravenously over ≥ 20 minutes.~- infusion set will be covered for blinding

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberet-Folic-500
Description: once a day dose, to start 5 days after the intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iberet-Folic-500
Description: once a day dose, to start 5 days after the intervention
Study: NCT01405170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: constituted powder for oral suspension 4 mg/mL single dose at 32 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: tablets 32 mg single dose
Study: NCT03960437

Intervention type: DRUG
Group type: OTHER
Intervention: Etelcalcetide
Description: Administered intravenously at the end of each dialysis session. Dosing ranges from 5 mg to 15 mg set by the patient's physician.
Study: NCT01157442

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cell phone sms text messaging
Description: At enrollment a study nurse will send the intervention group a weekly SMS message reminding them to attend antenatal care. Starting at 36 weeks gestational age, an automated bulk SMS management system, will send the intervention group 3 SMS text messages (using non descript slogans) each week by proxy reminding them to take their nevirapine in labor. From time of delivery to 6 weeks postpartum the women will aslo receive 3 SMS messages per week reminding them to attend their 6 week checkup and 6 week infant visit.Upon receiving these messages women in the intervention group can text back if they have any concerns or questions. These women would then receive phone calls from the study nurse triaged according to the women's needs.
Study: NCT03872960

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transfer to cardiac arrest centre
Description: Patients in the intervention arm will be taken directly to a the catheter lab of a heart attack centre.
Study: NCT05608590

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipiodol UltraFluid
Description: The investigational product is an oil-based contrast medium, Lipiodol® (Guerbet). Lipiodol® is a solution of ethyl esters of iodized fatty acids of poppy seed oil equivalent to 480mg I /ml and is a licensed contrast agent in the Netherlands (RVG 02806, see SmPC D2). The maximum amount of Lipiodol® per HSG procedure is 15 ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipiodol UltraFluid
Description: The investigational product is an oil-based contrast medium, Lipiodol® (Guerbet). Lipiodol® is a solution of ethyl esters of iodized fatty acids of poppy seed oil equivalent to 480mg I /ml and is a licensed contrast agent in the Netherlands (RVG 02806, see SmPC D2). The maximum amount of Lipiodol® per HSG procedure is 15 ml.
Study: NCT03358394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A human-interventional study
Description: The intervention was developed by Ahmed et al. (2017) and was adapted by the investigators for parents of children with T1D. The researcher has received permission form the author to use the script but, not the audio recordings. As a result, we contacted Saab et al. (2016) to get the permission to use the Arabic audio recording of Mindfulness exercises (i.e., introduction to mindfulness practice and mindfulness breathing).~The mindfulness script to be used in the current study is based on MBPT. In this study, we will be using the MBPT programme, but tailored to the needs of parents of children with T1D. One of the main changes in our study is that it will be delivered via the Internet. Participants in the original MBPT programme attended in-person sessions however, Rayan et al. (2016) delivered only the first two sessions in person and the rest via telephone

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A human-interventional study
Description: The intervention was developed by Ahmed et al. (2017) and was adapted by the investigators for parents of children with T1D. The researcher has received permission form the author to use the script but, not the audio recordings. As a result, we contacted Saab et al. (2016) to get the permission to use the Arabic audio recording of Mindfulness exercises (i.e., introduction to mindfulness practice and mindfulness breathing).~The mindfulness script to be used in the current study is based on MBPT. In this study, we will be using the MBPT programme, but tailored to the needs of parents of children with T1D. One of the main changes in our study is that it will be delivered via the Internet. Participants in the original MBPT programme attended in-person sessions however, Rayan et al. (2016) delivered only the first two sessions in person and the rest via telephone
Study: NCT03110952

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDENV-PIV
Description: Single-dose vial with pre-filled syringe, subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDENV-PIV
Description: Single-dose vial with pre-filled syringe, subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDENV-PIV
Description: Single-dose vial with pre-filled syringe, subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDENV-F17
Description: Single-dose vial with pre-filled syringe 0.5 mL administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDENV-F17
Description: Single-dose vial with pre-filled syringe 0.5 mL administered intramuscularly

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL vial
Study: NCT01138150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treximet
Description: One tablet of sumatriptan 85 mg and naproxen sodium 500 mg will be given upon subject presentation with an acute migraine attack and after blood levels have been drawn.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet of a sugar pill will be given upon subject presentation with an acute migraine attack and after blood levels have been drawn.
Study: NCT04410341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 MG
Description: Vildagliptin, an antidiabetic drug that inhibits the dipeptidyl peptidase- 4 (DPP-4), increases glucagon-like peptide-1 (GLP-1) and regulates blood glucose levels, favoring weight loss and lowering cardiovascular risk.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram 20 mg
Description: Escitalopram,Selective serotonin reuptake inhibitor- Cilostazol, a selective phosphodiesterase 3 (PDE3) inhibitor, acts as an antiplatelet agent and has been widely approved for treatment of intermittent claudication with peripheral arterial disease and for secondary prevention of ischemic stroke.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg
Description: Escitalopram,Selective serotonin reuptake inhibitor- Cilostazol, a selective phosphodiesterase 3 (PDE3) inhibitor, acts as an antiplatelet agent and has been widely approved for treatment of intermittent claudication with peripheral arterial disease and for secondary prevention of ischemic stroke.
Study: NCT01897597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 144807 high dose
Description: oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 144807 intermediate dose
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 144807 intermediate dose
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 144807 intermediate dose
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 144807 intermediate dose
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 144807 intermediate dose
Description: oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 144807 high dose
Description: tablet
Study: NCT01620983

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Arthritis Education
Study: NCT02592577

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T
Study: NCT01620983

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Study: NCT04807127

Intervention type: DRUG
Intervention: Immune checkpoint blockade
Description: ICI, administered as standard-of-care treatment
Study: NCT02530723

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: power training
Description: Resistance training machines with CAM devices will be used for training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: power training
Description: Resistance training machines with CAM devices will be used for training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: power training
Description: Resistance training machines with CAM devices will be used for training.
Study: NCT04807127

Intervention type: DRUG
Intervention: Targeted therapy
Description: TKI, administered as standard-of-care treatment

Intervention type: RADIATION
Intervention: Radiotherapy
Description: RT, administered as standard-of-care treatment
Study: NCT03535883

Intervention type: DRUG
Intervention: Novel Oral Anti-Coagulants
Description: Novel Oral Anti-Coagulant (NOAC) medications (i.e. Eliquis, Plavix, Xarelto etc.)
Study: NCT00929903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib hydrochloride
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT04915586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-pleural Alteplase 16mg with Pulmozyme (DNase) 5mg
Description: Intra-pleural Alteplase 16mg with Pulmozyme (DNase) 5mg for total 3 doses within 24 hours
Study: NCT04652921

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine-guanidinoacetic acid
Description: A dietary supplement provided as powder dissolved in a glass of water

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inulin
Description: A dietary supplement provided as powder dissolved in a glass of water